Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis

NCT00505778 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00505778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00505778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis
Lead sponsor
Warner Chilcott
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
July 31, 2009
Enrollment
1,027 (actual)
Sites
245

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis